Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Pasithea Therapeutics Corp. (KTTA)

Pasithea Therapeutics warrants KTTAW to expire September 17, 2026, delisted from Nasdaq

Neutral Impact 2 of 5 shareholder Written later

Pasithea Therapeutics said its warrants under symbol KTTAW will expire on September 17, 2026, under their terms and the warrant agency agreement with VStock Transfer, LLC. Unexercised warrants will stop being exercisable and will have no further value, and the warrants will cease trading on Nasdaq and be delisted and deregistered. The company's common stock, KTTA, will continue to trade on Nasdaq.

Key points

  • Warrants (KTTAW) expire on September 17, 2026
  • Unexercised warrants cease to be exercisable and have no further value
  • Warrants to be removed from Nasdaq listing via Form 25 filing
  • Common stock (KTTA) continues trading on Nasdaq

The filing

CompanyPasithea Therapeutics Corp. (KTTA)
Form8-K, current report
Filed with the SECSep 16, 2026, 4:06 PM ET
Accession number0001213900-26-100515

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 16, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.